Open Label, Phase I/II, Residual Edema Evaluation With 0.5mg and 2.0mg Ranibizumab Formulations (REEF)
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2016
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms REEF
- 23 Apr 2016 Time frame for primary endpoint changed from 12 months to 6 months.
- 17 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 07 Dec 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.